Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04358991 · ClinicalTrials.gov registry record
Pharmacokinetics of Ceftazidime-avibactam Among Critically-ill Patients Receiving CVVHDF
A clinical trial, sponsored by University of Pittsburgh.
- Completed
- Registry status
- 20
- Enrollment target
NCT04358991 is a clinical trial that has completed, run by University of Pittsburgh. The registered enrollment target is 20 participants.
The verdict
NCT04358991 has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- 20 participants
- Enrollment target
Study Summary
Ceftazidime-avibactam is used for treatment of invasive Gram-negative bacterial infections among critically ill patients, including those on continuous venovenous hemodiafiltration . However, dosing of ceftazidime-avibactam for these patients remains undefined. The purpose of this study was to evaluate the pharmacokinetics of ceftazidime and avibactam among critically-ill patients, including those receiving CVVHD. This is a registration of Dr. Shields' exempt project under IRB approved research study STUDY19040363
Interventions
- DRUG Ceftazidime-avibactam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-01-01 |
| Est. Completion | 2019-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04358991
The ClinicalTrials.gov registry entry for NCT04358991 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ceftazidime-avibactam is the first listed.
NCT04358991 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04358991 about?
NCT04358991 is a clinical study titled "Pharmacokinetics of Ceftazidime-avibactam Among Critically-ill Patients Receiving CVVHDF". Ceftazidime-avibactam is used for treatment of invasive Gram-negative bacterial infections among critically ill patients, including those on continuous venovenous hemodiafiltration . However, dosing of ceftazidime-avibactam for these patients remains undefined. The purpose of this study was to evalu...
What is the current status of trial NCT04358991?
This trial is currently completed. The enrollment target is 20 participants. The study started on 2017-01-01. Estimated completion is 2019-12-31.
What interventions are being tested in trial NCT04358991?
The interventions under investigation include: Ceftazidime-avibactam (DRUG).
Who is sponsoring clinical trial NCT04358991?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.